The Food and Drug Administration (FDA) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
Document
Determination That BIAXIN XL Oral Tablets Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This de...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
80 FR 52048
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Determination That BIAXIN XL Oral Tablets Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” thefederalregister.org (August 27, 2015), https://thefederalregister.org/documents/2015-21236/determination-that-biaxin-xl-oral-tablets-were-not-withdrawn-from-sale-for-reasons-of-safety-or-effectiveness.